Email this article 
Post a Comment Effect of thiazolidinediones on dislipidemia in patients with metabolic syndrome depending on the gene PPAR-gamma rs1801282 polymorphism
- Authors: Eremenko T.V.1, Kotova S.M.1, Vorokhobina N.V.1, Matsievskiy N.A.1, Matezius I.Y.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 10, No 4 (2018)
- Pages: 37-42
- Section: Original research
- URL: https://journal-vniispk.ru/vszgmu/article/view/10626
- DOI: https://doi.org/10.17816/mechnikov201810437-42
- ID: 10626
Cite item
Full Text
Abstract
Background. To evaluate the effect of thiazolidinediones on lipid spectrum of blood in patients with metabolic syndrome depending on gene polymorphism rs1801282.
Materials and methods. The study included 109 patients with newly diagnosed metabolic syndrome. All subjects in the study underwent general clinical, laboratory methods, presence of polymorphism rs1801282 of the PPAR-gamma gene was also determined. All patients were recommended to keep a diet, increase physical activity and receiving pioglitazone 30 mg per day for the period of 3 months.
Results.During therapy with pioglitazone it was noted that the degree of reduction of triglycerides was more pronounced in patients with IGT carrying rs1801282 -1.2 (-1.7; -1.1) versus -0.2 (-0.4; 0.0) in patients with wild genotype (p < 0.001) as well as in patients with type 2 diabetes, carries of polymorphic allele -1.3 (-1.6; -1.2) versus -0.2 (-0.3; 0.0) in patients with wild genotype (p < 0.001).
Conclusion. As a result of administering pioglitazone, an improvement in the lipid spectrum of the examined patients was noted. The maximum degree of reduction of triglycerides was observed in patients carrying rs1801282 polymorphic allele compared with the wild genotype.
Full Text
##article.viewOnOriginalSite##About the authors
Tatyana V. Eremenko
North-Western State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: eremenkotanja2007@rambler.ru
ORCID iD: 0000-0002-2279-6324
SPIN-code: 4499-4789
assistant of the department of endocrinology named after V.G.Baranov
Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015Svetlana M. Kotova
North-Western State Medical University named after I.I. Mechnikov
Email: Svetlana.Kotova@szgmu.ru
SPIN-code: 9568-4655
Scopus Author ID: 466298
professor of the department of endocrinology named after V.G.Baranov
Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015Natalya V. Vorokhobina
North-Western State Medical University named after I.I. Mechnikov
Email: natvorokh@mail.ru
SPIN-code: 4062-6409
Scopus Author ID: 291621
professor of the department of endocrinology named after V.G.Baranov
Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015Nikolay A. Matsievskiy
North-Western State Medical University named after I.I. Mechnikov
Email: nicomedicus@mail.ru
ORCID iD: 0000-0003-4486-4778
SPIN-code: 7884-5099
ResearcherId: 761194
assistant professor of the department of endocrinology named after V.G.Baranov
Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015Irina Yu. Matezius
North-Western State Medical University named after I.I. Mechnikov
Email: Irina.Matesius@szgmu.ru
SPIN-code: 7421-1610
assistant professor of the department of endocrinology named after V.G.Baranov
Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015References
- Симонова Г.И., Мустафина С.В., Печенкина Е.А. Распространенность метаболического синдрома в Cибири: популяционное исследование в г. Новосибирске // Сибирский научный медицинский журнал. – 2011. – Т. 31. – № 5. – C. 100–106. (Simonova GI, Mustafina SV, Pechenkina EA. The metabolic syndrome prevalence in Siberia: population-based study in Novosibirsk. Bulletin of Siberian Medicine. 2011;31(5):100-106. (In Russ.))
- Azizi F, Hadaegh F, Khalili D, et al. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med. 2010;13(5):426-428.
- Оганов Р.Г., Денисов И.Н., Симаненков В.И., и др. Коморбидная патология в клинической практике. Клинические рекомендации // Кардиоваскулярная терапия и профилактика. – 2017. – Т. 16. – № 6. – С. 5–56. (Oganov RG, Denisov IN, Simanenkov VI, et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.)). https://doi.org/10.15829/1728-8800-2017-6-5-56.
- Ганелина И.Е., Липовецкий Б.М., Чурина С.К., и др. Атеросклероз венечных артерий и ишемическая болезнь сердца: руководство / Под ред. И.Е. Ганелина. – 2-е изд., перераб. и доп. – СПб.: Изд-во СЗГМУ им. И.И. Мечникова, 2012. – 320 c.: ил. (Ganelina IE, Lipoveckij BM, Churina SK, et al. Ateroskleroz venechnyh arterij i ishemicheskaja bolezn’ serdca: rukovodstvo. Ed. by I.E. Ganelina. 2nd ed. Saint Petersburg: Izd-vo SZGMU im. I.I. Mechnikova; 2012. 320 p. (In Russ.))
- Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care. 1996;19(4):390-393. https://doi.org/10.2337/diacare.19.4.390.
- Grundy SM, Vega GL, Tomassini JI, et al. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009;104(4):548-553. https://doi.org/10.1016/j.amjcard.2009.04.018.
- Kastelein JJP, Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-3009.
- AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. https://doi.org/10.1056/NEJMoa1107579.
- Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. https://doi.org/10.2217/clp.10.84.
- Lee WJ, Kim M, Park HS, et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun. 2006;340(1):291-295. https://doi.org/10.1016/j.bbrc.2005.12.011.
- Risérus U, Sprecher D, Johnson T, et al. Activation of PPAR delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-339. https://doi.org/10.2337/db07-1318.
- Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the IDF Task Force on Epidemiology and Prevention; NHLBI; AHA; WHF; IAS; and IASO. Circulation. 2009;120(16):1640-1645. https://doi.org/10.14341/2071-8713-5281.
Supplementary files
